Wockhardt get tentative nod from USFDA for Duloxetine, stk up

MUMBAI: Wockhardt has received tentative approval from the USFDA for Duloxetine, a generic version of depression drug Cymbalta. The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same.

The stock was at Rs 401.65, up 1.04 per cent on the NSE. It touched a high of Rs 406.80 and low of Rs 397.60 in trade so far.